Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHe HuangWZWeiyan Zheng

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows high response rates in AML patients treated with reduced intensive regimen plus venetoclax, indicating lower toxicity levels.

Key Points

  • To evaluate the efficacy of a reduced intensive chemotherapy regimen combined with venetoclax in adult patients with acute myeloid leukemia.
  • Conducted a retrospective single-center analysis
  • Included 36 adult AML patients treated with reduced intensive IA and venetoclax
  • Assessed overall response rate and analyzed survival using Kaplan–Meier methods.
  • Overall response rate after two cycles was 97%
  • Median event-free survival was 34.4 months
  • High incidence of neutropenia (95%) and fever (89%) was observed.
  • Efficacy was comparable to standard regimens but with reduced cardiac toxicity.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5bahttps://doi.org/10.1182/blood-2025-6908
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India2025
  2. 2Venetoclax combined with cladribine, idarubicin, cytarabine ( <scp>CLIA</scp> ‐ <scp>VEN</scp> ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia2025
  3. 3Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis2026 · 1 citations
  4. 4Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025 · 1 citations
  5. 5[Venetoclax combined with dose-reduced HAD as induction treatment for patients with de-novo acute myeloid leukemia].2024